Elucidation of the HCV genome analysis and drug resistance mechanism by the next generation sequencer
Project/Area Number |
24590964
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | University of Yamanashi |
Principal Investigator |
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | C型肝炎 / 遺伝子変異 / 薬剤耐性変異 / DAAs / 次世代シーケンサー / quasispecies |
Outline of Final Research Achievements |
With the recent development of highly potent and safe direct antiviral agents (DAAs), viral response (SVR) rate in HCV patients has been significantly improved. Therapeutic effect of PEG-IFN + RBV + NS3-4 protease inhibitor (TVR / SMV) was associated is a PEG-IFN + RBV, associated with HCV NS5A interferon sensitivity determining region (ISDR), -interferon/ribavirin resistance determining region (IRRDR) and core amino acid mutations (R70Q).Also R70Q mutation was associated with IL28B SNP related to IFN response.We revealed that drug resistance mutations to DAA is existed in the DAA naive cases, it was often found in IFN-sensitive strains.In the analysis by the next generation sequencer, HCV was a collection of a large number of variants (quasispecies), drug resistance mutations emerged from the wild-type strain, and Composition of major population greatly changed as the acquired resistant and altered composition were maintained thereafter.
|
Report
(4 results)
Research Products
(48 results)
-
[Journal Article] Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection.2014
Author(s)
Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Enomoto N.
-
Journal Title
Hepatol Res.
Volume: Feb 25
Issue: 14
DOI
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression.2013
Author(s)
Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.
-
Journal Title
J Virol.
Volume: 87(23)
Issue: 23
Pages: 12541-12551
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
[Journal Article] Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.2012
Author(s)
Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Izumi N
-
Journal Title
J Hepatol
Volume: 56
Pages: 602-608
Related Report
Peer Reviewed
-
[Journal Article] Comprehensive analysis for viral elements and IL28B polymorphisms in response to peginterferon plus ribavirin therapy in HCV-1b infection.2012
Author(s)
Maekawa S, Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N
-
Journal Title
Hepatology
Volume: 56
Pages: 1611-1621
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] IL28B (IFNλ-3) and IFN-α Synergistically Inhibit HCV Replication.
Author(s)
Shindo H, Maekawa S, Komatsu N, Komase K, Miura M, Kadokura M, Sueki R, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N
Organizer
The 3rd International Forum
Place of Presentation
京王プラザホテル(東京都)
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-